anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: INSULIN DETEMIR
Trial phase: Phase 2
ATC code: A10AE05
SMILES: CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 20IU of Insulin Detemir taken twice per day (40IU total per day)

Insulin detemir: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
Eligibility criteria:
Inclusion Criteria:

Age 50-89
Diagnosed with mild cognitive impairment, or mild/moderate AD

Exclusion Criteria:

Excessively high or low blood pressure, heart rate
Pre-existing diabetes not controlled by exercise/diet
Previous/current use of insulin
Significant elevations in lipids, liver enzymes
Menstrual period within the last 12 months
Significant neurological or medical disorder (other than AD)
Significant use of nasal decongestants
Current use of anti-psychotic, anti-convulsive, anxiolytic, glucocorticoids, or sedative medications
Intervention: Salicylhydroxamic Acid
Trial phase: Phase 2
SMILES: O=C(NO)c1ccccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: 1 mock injection per month for 12 months
Eligibility criteria:
Inclusion Criteria:

Ability to provide informed consent and comply with the protocol.
Diagnosis of bilateral geographic atrophy (GA) of the macula secondary to age-related macular degeneration, confirmed within 14 days prior to randomization.
Study eye: Maximum best-corrected visual acuity (BCVA) of 55 letters (20/80 Snellen equivalent) and a minimum BCVA of 20 letters (20/400 Snellen equivalent) at screening
BCVA of 20 letters (20/400 Snellen equivalent) or better in the non treated eye at screening without conditions other than AMD that, in the opinion of the investigator, could cause a rapid loss of vision.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Any history or current evidence of exudative ("wet") AMD in study eye.
Retinal disease other than AMD in the study eye.
Any ophthalmologic condition in study eye that reduces the clarity of the media and that, in the opinion of the Investigator interferes with ophthalmologic examination, such as advanced cataract or corneal abnormalities.
Any ophthalmologic condition in study eye that prevents adequate imaging of the retina judged by the site or reading center.
A history or current medical diagnosis of glaucoma or ocular hypertension in study eye.
Any ophthalmic condition in study eye that may require surgery during the study period.
Current ocular or periocular infection in the study eye.
History of any disease or current use of medication expected to cause systemic or ocular immunosuppression, such as RESTASIS®.
History of uveitis or endophthalmitis in the study eye.
History of intraocular surgery (including cataract surgery) in the study eye within 90 days prior to dosing.
History of intravitreal or periocular injection in the study eye at anytime.
Participation in another interventional clinical study, or use of any experimental treatment for AMD or any other investigational new drug within 6 weeks or during active period of drug (whichever is longer) prior to the start of study treatment.
History of any medical or psychiatric condition, or substance abuse, that in the Investigator's opinion is likely to interfere with the patient's participation in the study, or likely to cause serious adverse events during the study.
Women of child bearing potential UNLESS they are using a highly effective method of birth control.
Known or suspected allergy or hypersensitivity to fluorescein or other injectables.
Other protocol-defined exclusion criteria may apply.
Intervention: Osoresnontrine
Trial phase: Phase 1
SMILES: O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Young healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Eligibility criteria:
Inclusion criteria:

1. Healthy male/female subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Intervention: Osoresnontrine
Trial phase: Phase 1
SMILES: O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Young healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Eligibility criteria:
Inclusion criteria:

1. Healthy male/female subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Intervention: Osoresnontrine
Trial phase: Phase 1
SMILES: O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Elderly healthy subjects received 25 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Eligibility criteria:
Inclusion criteria:

1. Healthy male/female subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Intervention: Osoresnontrine
Trial phase: Phase 1
SMILES: O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Elderly healthy subjects received 50 mg of BI 409306 film-coated tablets orally after an overnight fast once daily for 14 days
Eligibility criteria:
Inclusion criteria:

1. Healthy male/female subjects

Exclusion criteria:

1. Any relevant deviation from healthy conditions
Intervention: Macimorelin
Trial phase: Phase 2
ATC code: V04CD06
SMILES: CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Macimorelin: Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
Eligibility criteria:
Inclusion Criteria:

Subjects ≥18 years of age with histological diagnosis of incurable cancer (solid tumor),
ECOG performance status of 0-2,
Presence of cancer-related cachexia defined as an involuntary weight loss of at least 5% of the pre-illness body weight over the previous 6 months, and
Provide written informed consent prior to screening.

Exclusion Criteria:

Obesity (body weight >140 Kg);
Recent active excessive alcohol or illicit drug use;
Severe depression as determined by the investigator;
Other causes of cachexia such as: Liver disease (AST or ALT > 3x normal levels); renal failure (creatinine >1.5 mg/dL), untreated thyroid disease, class III-IV CHF, AIDS, severe COPD requiring use of home O2;
Inability to increase food intake (e.g., esophageal obstruction, intractable nausea and vomiting);
Any condition that would prevent the subject from performing the research procedures (e.g. unstable coronary artery disease);
Use of growth hormone, megestrol, Marinol, or any other anabolic agents, appetite stimulants (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feeding, or parenteral nutrition during the 1 month prior to entering the study;
Recent administration (less than 1 week) of highly emetogenic chemotherapy (Hesketh scale class 4-5); subjects may otherwise be undergoing chemotherapy.
Being female and pregnant, breast-feeding or of childbearing potential. (Note: Lack of childbearing potential for female patients is satisfied by: a) being post menopausal; b) being surgically sterile; c) practicing contraception with an oral contraceptive, intra-uterine device, diaphragm, or condom with spermicide for the duration of the study; or d) being sexually inactive. Confirmation that the patient is not pregnant will be established by a negative serum hCG pregnancy test at the time of enrollment.
Co-administration of drugs that prolong QT interval, CYP3A4 inducers, QTc equal to or greater than 450ms at screening, or other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber).

Conditions that would preclude from successfully scanning subjects in MRI:

Claustrophobia (this would make lying in the scanner very uncomfortable); b. having a pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants; c. History of Seizures d. History of head injuries resulting in loss of consciousness > 10 minutes.
Intervention: Elocon
Trial phase: Phase 4
ATC code: D07AC13 | D07XC03 | R01AD09 | R03AK09 | R03BA07
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(OC(=O)c1ccco1)C(=O)CCl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.

mometasone furoate: 2 sprays/nostril BID
Eligibility criteria:
Inclusion Criteria:

- The subject must fulfill all of the following conditions or characteristics to be considered for enrollment:

Male or female between ages 21 - 70 years residing in the Boston area

History of chronic rhinosinusitis (symptoms for at least 3 months). Subject must have two or more of the following:

Facial pain/pressure or headache
Nasal congestion
Anterior or posterior nasal drainage
Hyposmia/anosmia
Abnormal CT scan in at least 2 sinuses areas within 3 months

Evidence of bilateral polyps or polypoid mucosa (on nasal endoscopy) with minimum polyp/polypoid score of 4 (see scoring system below).

Exclusion Criteria:

4. History of suggestive of immunodeficiency (i.e. those who have had > one pneumonia in the past 12 months or those with known immune deficiency).
History of cystic fibrosis, Kartagener's syndrome, immotile cilia syndrome, hypogammaglobulinemia or bleeding disorder
URI within six weeks prior to enrollment
Intranasal cocaine use
Pregnancy (if applicable

History of fainting

MEDICATION EXCLUSIONS prior to NP biopsies:

Use of prescription blood thinners
Use of systemic glucocorticoids for two weeks prior to enrollment
Use of intranasal corticosteroids and anticholinergics for three days prior to enrollment
Use of an antibiotic for three days prior to enrollment
Use of antihistamines for one week prior to enrollment
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 126
Group description: MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 133
Group description: MP-214 6mg: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 67
Group description: MP-214 9mg: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 83
Group description: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg or 6mg) of MP-214 for four weeks, then flexible dose (1.5-9mg) of MP-214
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia

Patients who meet at least one of the following:

current diagnosis of schizophrenia of chronic phase
between 65 and 74 years of age
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: MP-214 3mg: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Cariprazine
Trial phase: Phase 2 | Phase 3
ATC code: N05AX15
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 42
Group description: MP-214: Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214
Eligibility criteria:
Inclusion Criteria:

Written informed consent obtained from the patient before the initiation of any study-specific procedures
Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
Patients who receive 1 or more antipsychotic drugs
Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)

Exclusion Criteria:

Patients with a DSM-IV-TR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Intervention: Prochlorperazine
Trial phase: Phase 4
ATC code: N05AB04
SMILES: CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 93
Group description: Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills

Prochlorperazine 10mg: One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
Eligibility criteria:
Inclusion Criteria:

18 years or older

Headache must meet the IHS criteria for migraine or probable migraine

2 out of 4 of following:

Unilateral location
Throbbing (pulsating) quality
Moderate to severe intensity (inhibits/prohibits daily activities)
Exacerbation with moderate activity or mild activity

During HA, at least 1 out of 3 of following:

Nausea and/or vomiting
Photophobia
Phonophobia

Exclusion Criteria:

Known allergy to study medications
Pregnancy
< 18 years old
Inability to provide written, informed consent
Patients with positive lumbar puncture or positive CT scan for suspected secondary headache
History of peptic ulcer disease
History of liver failure
History of coagulopathy
Gastrointestinal bleeding within the last 3 months
Previous gastrointestinal bleeding with non-steroidal anti-inflammatory medications
Ingestion of other pain medications within the previous six hours deemed to put the patient at risk of exceeding a toxic dose of ASA or acetaminophen (> 100mg/kg for ASA or acetaminophen)
Vomiting within one hour of receiving oral study medications.
Intervention: Misoprostol
Trial phase: Not Applicable
ATC code: A02BB01 | G02AD06 | M01AE56
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 130
Group description: Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal

Vaginal Misoprostol: Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
Eligibility criteria:
Inclusion Criteria:

Clinical candidate for labor induction utilizing either misoprostol or oxytocin
Greater than or equal to 18 years of age
Multiparous
Singleton gestation;
Greater than 37 weeks gestation;
Cephalic presentation

Exclusion Criteria:

Any clinical contraindication to misoprostol as induction drug
Age less than 18 years
Contraindication to vaginal birth
Nonreassuring fetal heart rate tracing
Prior uterine surgery
Active labor
Active maternal bleeding
Chorioamnionitis (infection)
Intervention: Misoprostol
Trial phase: Not Applicable
ATC code: A02BB01 | G02AD06 | M01AE56
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 42
Group description: Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.

Misoprostol: Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
Eligibility criteria:
Inclusion Criteria:

Age greater or equal to 18 years
Fluency in English or Spanish
Intrauterine pregnancy between 11 0/7 and 15 0/7 on the day of the abortion procedure
Desire for pregnancy termination
Ability to return for abortion procedure 24-48 hours after the preoperative visit

Exclusion Criteria:

Allergy or contraindication to study agents
Requirement of general anesthesia to perform the abortion
Diagnosis of missed abortion, spontaneous abortion, incomplete abortion, or threatened abortion at time of initial preoperative evaluation